The Role of C-Reactive Protein as a Risk Predictor of Coronary Atherosclerosis: Implications from the JUPITER Trial
Much controversy surrounds the use of high-sensitivity C-reactive protein (hs-CRP) as a marker of cardiovascular (CV) risk. Although data regarding the association of hs-CRP with CV disease is extensive and consistent, its role in clinical practice remains unclear. The American Heart Association (AHA) recently published a scientific statement regarding criteria for evaluation of novel markers of CV risk. This article provides a comprehensive review of data regarding hs-CRP as a risk marker for CV disease in the context of these AHA criteria. The impact of the JUPITER trial on the utility of hs-CRP as a risk marker is emphasized. The review concludes with an evidence-based statement regarding the current role of hs-CRP in CV risk prediction.
Keywordshs-CRP Cardiovascular disease Coronary heart disease Cardiovascular risk prediction Statins
The authors report no potential conflicts of interest relevant to this article.
Dr. Antonio Gotto, Editor-in-Chief of Current Atherosclerosis Reports, reviewed this article and provided comments and suggestions. He was a member of the JUPITER Steering Committee, for which he received honoraria, and has served as a consultant for AstraZeneca. He has no financial relationship with the manufacturer of the hs-CRP test.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 5.•• Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto Jr AM, Kastelein JJP, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195. This is the main article of the JUPITER study. It showed the rosuvastatin therapy in those “apparently” healthy population with elevated hs-CRP of >2 mg/L and low LDL (<130 mg/dL) had decreased cardiovascular risk with the use of rosuvastatin.PubMedCrossRefGoogle Scholar
- 7.• Bajpai A, Goyal A, Sperling L. Should we measure C-reactive protein on Earth or just on JUPITER? Clin Cardiol. 2010;33(4):190–8. This article provides a comprehensive review of the data regarding cardiovascular risk and hs-CRP with an emphasis on the JUPITER trial .It concludes with an evidence-based analysis of the role of hs-CRP in cardiovascular risk assessment.PubMedCrossRefGoogle Scholar
- 9.Kushner I. C-reactive protein and the acute-phase response. Hosp Pract (Off ed). 1990;25(3):13.Google Scholar
- 20.•• Zacho J, Tybjaerg-Hansen A, Jensen JS, Grande P, Sillesen H, Nordestgaard BG. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med. 2008;359(18):1897. This landmark genetic study showed that polymorphisms in the CRP gene are associated with marked increases in CRP levels but with no increase risk of ischemic vascular disease.PubMedCrossRefGoogle Scholar
- 24.May M, Lawlor D, Brindle P, Patel R, Ebrahim S. Cardiovascular disease risk assessment in older women: can we improve on Framingham? British Women’s Heart and Health prospective cohort study. Br Med J. 2006;92(10):1396.Google Scholar
- 33.•• Pencina MJ, D’Agostino Sr RB, Jr D’Agostino RB, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008;27(2):157–72. This article intoduces the Net Reclassification Index (NRI) as a novel way of measuring the additive effect of a variable to a model in reclassifying individuals to different risk category.PubMedCrossRefGoogle Scholar
- 36.Cook N. Comments on ‘Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond’ by MJ Pencina et al., Statistics in Medicine (DOI. Stat Med. 2008;27(2):191–5.Google Scholar
- 38.McMurray J, Kjekshus J, Gullestad L, Dunselman P, Hjalmarson A, Wedel H, et al. Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis. Circulation. 2009;120(22):2188.PubMedCrossRefGoogle Scholar
- 46.•• Kappagoda CT, Amsterdam EA. Another look at the results of the JUPITER trial. Am J Cardiol. 2009;104(11):1603–5. This articles analyzes the methodology and results of the JUPITER study. It shows significant epidemiologic and methodologic inconsistencies in the JUPITER study that warrant consideration. The article emphasizes that the study population was not a healthy population and that standard medical care was not provided to the population that could have changed the result of the study significantly.PubMedCrossRefGoogle Scholar
- 48.• Sattar N, Preiss D, Murray H, Welsh P, Buckley B, de Craen A, Seshasai S, McMurray J, Freeman D, Jukema J. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010. This study is a meta-analysis of the risk of diabetes mellitus with statin therapy. It concludes that statin therapy is associated with a slightly increased risk of development of diabetes, but the risk is low.Google Scholar